A 3-Arm Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study of NVK-002 in Children With Myopia
Phase of Trial: Phase III
Latest Information Update: 24 Dec 2017
At a glance
- Drugs NVK-002 (Primary)
- Indications Myopia
- Focus Registrational; Therapeutic Use
- Acronyms CHAMP
- Sponsors Nevakar
- 30 Nov 2017 New trial record
- 21 Nov 2017 Planned number of patients changed to 500, according to a Nevakar media release.
- 21 Nov 2017 According to a Nevakar media release, first patient has been dosed.